NEW PRODUCTS
| Catalog No | Chemical Name | CAS Number | Purity | Chemical Structure |
|---|---|---|---|---|
| 90731 | GDC-0810 ( Brilanestrant , ARN-810 ) | 1365888-06-7 | ≧98.0% |  |
| GDC-0810 (Brilanestrant, ARN-810, RG6046) is a selective estrogen receptor degrader ( | ||||
| 102703 | AZD-8835 | 1620576-64-8 | ≧98.0% |  |
| AZD8835 is a potent and selective inhibitor of PI3Kalpha and PI3Kdelata with excellen | ||||
| 611902 | PF-04979064 | 1220699-06-8 | ≧98.0% |  |
| PF-04979064 is a potent and selective PI3K/mTOR dual kinase inhibitor with an IC(50) | ||||
| 6111110 | Nastorazepide | 209219-38-5 | 98% |  |
| Nastorazepide (Z-360) is a selective, orally available, 1,5-benzodiazepine-derivative | ||||
| 174192 | RG7800 ( RO6885247 ) | 1449598-06-4 | ≧98.0% |  |
| RG7800(RO6885247) is a small molecule modifier of survival motor neuron 2 splicing. | ||||
| 90734 | RSM932A | 850807-63-5 | ≧98.0% | .png) |
| Choline kinase α (CHKA; here designated as ChoKα) is the first enzyme in the CDP-ch | ||||
| 184321 | Ensartinib ( X396 ) | 1370651-20-9 | >98% | _1370651-20-9.png) |
| Ensartinib is an orally available small molecule inhibitor of the receptor tyrosine k | ||||
| 185235 | Trilaciclib (G1T28) | 1374743-00-6 | >98% |  |
| TRILACICLIB (G1T28), A HIGHLY POTENT, TRANSIENT CDK 4/6 INHIBITOR WITHIC50s OF 1 nM A | ||||
| 188281 | Arimoclomol maleate | 289893-26-1 | 98% |  |
| Arimoclomol, also known as BRX-220, is potentially useful for the treatment of Nieman | ||||
| 1811162 | PF-05231023 | 1037589-69-7 | >98% |  |
| PF-05231023 is a long-acting FGF21 mimetic. PF-05231023 decreases body weight and imp | ||||
| 1811211 | Anlotinib HCl ( AL-3818 ) | 1360460-82-7 | ≧98.0% | _1360460-82-7.png) |
| Anlotinib is a novel oral tyrosine kinase inhibitor (TKI) targeting c-kit, platelet-d | ||||
| 191122 | Tafenoquine ( WR 238605 ) | 106635-80-7 | ≧98.0% |  |
| Tafenoquine is being investigated as a potential treatment for malaria, as well as fo | ||||